LSL Pharma Group (TSXV:LSL) Net Income (Continuing Operations): C$-5.48 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:LSL LSL Pharma Group Inc TSXV:LSL
48 GF Score
Price C$0.36
GF Value C$0.74
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is LSL Pharma Group Net Income (Continuing Operations)?

LSL Pharma Group TSXV:LSL -1.39% 48 Net Income (Continuing Operations) is C$-5.48 Mil as of Mar. 2026. GuruFocus rates TSXV:LSL with a GF Score™ of 48/100 and a GF Value™ of C$0.74 (Possible Value Trap). The stock has 6 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. LSL Pharma Group's Net Income (Continuing Operations) for the three months ended in Mar. 2026 was C$-2.82 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 was C$-5.48 Mil.

LSL Pharma Group  (TSXV:LSL) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

LSL Pharma Group Net Income (Continuing Operations) Related Terms

LSL Pharma Group Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for LSL Pharma Group's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LSL Pharma Group Net Income (Continuing Operations) Chart

LSL Pharma Group Annual Data
Trend Sep20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial -1.78 -8.06 -8.47 3.32 -2.82

LSL Pharma Group Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.39 -1.18 -1.10 -2.82
TSXV:LSL
48GF Score
LSL Pharma Group Inc TSXV:LSL
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LSL Pharma Group Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-5.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of C$-5.48 Mil mean?
LSL Pharma Group (TSXV:LSL) has a Net Income (Continuing Operations) of C$-5.48 Mil as of Mar. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on LSL Pharma Group and its competitors.
Is LSL Pharma Group's Net Income (Continuing Operations) too high?
LSL Pharma Group's current Net Income (Continuing Operations) is C$-5.48 Mil. Overall, LSL Pharma Group has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LSL Pharma Group's Net Income (Continuing Operations) compare to ZTS?
LSL Pharma Group's Net Income (Continuing Operations) of C$-5.48 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Drug Manufacturers company?
A good Net Income (Continuing Operations) depends on the Drug Manufacturers industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on LSL Pharma Group and its competitors. LSL Pharma Group's current Net Income (Continuing Operations) is C$-5.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LSL Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, LSL Pharma Group (TSXV:LSL) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.74, compared to a current price of C$0.36 — trading 52% below its estimated fair value. The current Net Income (Continuing Operations) is C$-5.48 Mil. LSL Pharma Group's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For LSL Pharma Group (TSXV:LSL), the current Net Income (Continuing Operations) is C$-5.48 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?

Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued. The current stock price of C$0.36 is trading 52% below its estimated GF Value™ of C$0.74. GuruFocus considers LSL Pharma Group to be Possible Value Trap.

Key valuation signals for TSXV:LSL:

  • Net Income (Continuing Operations): C$-5.48 Mil
  • GF Value™: C$0.74 vs. price of C$0.36 (52% below fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LSL Pharma Group Business Description

Address 540, rue d\'Avaugour, Bureau 1800, Boucherville, QC, CAN, J4B 0G6
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
48GF Score

Get the complete analysis for TSXV:LSL

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.36
Price
C$0.74
GF Value